期刊文献+

急性ST段抬高型心肌梗死患者直接经皮冠脉介入治疗术中慢血流/无复流的危险因素分析 被引量:19

Risk factors of slow/no reflow in patients with acute ST-segment elevation myocardial infarction during direct percutaneous coronary intervention
暂未订购
导出
摘要 目的探讨急性ST段抬高型心肌梗死(STEMI)直接经皮冠状动脉介入治疗(PCI)术中慢血流/无复流的危险因素。方法回顾性纳入郑州市第七人民医院心内科于2017年2月至2018年6月因STEMI行直接PCI的患者212例,根据PCI术中冠状动脉血流分为血流正常组和慢血流/无复流组,比较两组患者临床病史、血液生化指标、心脏超声资料及PCI资料,应用二分类logistic回归模型分析STEMI患者直接PCI术中慢血流/无复流的危险因素,绘制受试者工作特征曲线(ROC)确定预测慢血流/无复流的最佳截断点。结果慢血流/无复流组患者共47例(22.2%),与血流正常组相比,慢血流/无复流组患者糖尿病病史和吸烟史的比例均较高(P均<0.001),全球急性冠状动脉事件注册(GRACE)评分(P=0.002)、同型半胱氨酸(P<0.001)、纤维蛋白原(P=0.006)、N末端脑钠肽前体(P=0.004)均较高,肌酐清除率(P=0.008)较低,对比剂用量(P=0.018)较多,手术时间(P<0.001)较长,血栓抽吸(P=0.008)、单纯经皮冠状动脉腔内成形术(P=0.007)、应用主动脉内球囊反搏(P=0.014)比例均较高。多因素logistic回归分析结果显示,糖尿病病史(OR=3.676,95%CI:1.893~6.244,P=0.002)、吸烟史(OR=2.843,95%CI:1.902~5.632,P=0.005)、GRACE评分(OR=3.676,95%CI:1.893~6.244,P=0.002)、同型半胱氨酸(OR=5.133,95%CI:2.314~19.943,P=0.001)和纤维蛋白原(OR=3.684,95%CI:2.106~14.988,P=0.009)是STEMI患者直接PCI术中慢血流/无复流的独立危险因素。GRACE评分预测慢血流/无复流的最佳截断点为129.5分(AUC=0.629,敏感度75.0%,特异度45.5%),同型半胱氨酸的最佳截断点为13.8μmol/L(AUC=0.823,敏感度77.8%,特异度86.8%),纤维蛋白原的最佳截断点为2.13 g/L(AUC=0.622,敏感度为75.0%,特异度为47.1%)。结论糖尿病病史、吸烟史、GRACE评分、同型半胱氨酸和纤维蛋白原是STEMI患者直接PCI术中慢血流/无复流的危险因素,同型半胱氨酸可能是预测PCI术中慢血流/无复流的有效指标。 Objective To investigate the risk factors of slow/no reflow in patients with acute ST-segment elevation myocardial infarction(STEMI)during percutaneous coronary intervention(PCI).Methods A total of 212 patients who underwent direct PCI for STEMI from February 2017 to June 2018 in Zhengzhou Seventh People's Hospital were retrospectively included,and were divided into normal blood flow group and slow blood flow group according to coronary blood flow during PCI.In the no-reflow group,the clinical history,blood biochemical parameters,cardiac ultrasound data,and PCI data of the two groups were compared.The two-class logistic regression model was used to analyze the risk factors of slow blood flow/no reflow during direct PCI in STEMI patients.The operating characteristic curve(ROC)was used to determine the optimal truncation point for predicting slow/no reflow.Results There were 47 patients(22.2%)in the slow blood flow/no reflow group.Compared with the normal blood flow group,the proportion of patients with diabetes and smoking history was higher in the slow blood flow/no reflow group(all P<0.001).Global acute coronary event registration(GRACE)score(P=0.002),homocysteine(P<0.001),fibrinogen(P=0.006),N-terminal B-type natriuretic peptide(P=0.004))Are higher,creatinine clearance(P=0.008)is lower,contrast agent dosage(P=0.018)is more,operation time(P<0.001)is longer,thrombus aspiration(P=0.008),pure percutaneous coronary The proportion of intra-arterial angioplasty(P=0.007)and intra-aortic balloon counterpulsation(P=0.014)were higher.Multivariate logistic regression analysis results showed a history of diabetes(OR=3.676,95%CI:1.893~6.244,P=0.002),smoking history(OR=2.843,95%CI:1.902~5.632,P=0.005),GRACE score(OR=3.676,95%CI:1.893~6.244,P=0.002),homocysteine(OR=5.133,95%CI:2.314~19.943,P=0.001),and fibrinogen(OR=3.684,95%CI:2.106~14.988,P=0.009)is an independent risk factor for slow/no reflow during direct PCI in STEMI patients.The GRACE score predicts the best cutoff point for slow blood flow/no reflow as 129.5 points(AUC=0.629,sensitivity 75.0%,specificity 45.5%),and the best cutoff point for homocysteine is 13.8μmol/L(AUC=0.823,sensitivity 77.8%,specificity 86.8%),the best cut-off point of fibrinogen is 2.13 g/L(AUC=0.622,sensitivity 75.0%,specificity 47.1%).Conclusions Diabetes history,smoking history,GRACE score,homocysteine and fibrinogen are risk factors for slow/no reflow during direct PCI in STEMI patients.Homocysteine may be a predictor of slow blood during PCI.Effective index of flow/no reflow.
作者 丁琦 王淑红 冯晔子 黄新新 张欢欢 Ding Qi;Wang Shuhong;Feng Yezi;Huang Xinxin;Zhang Huanhuan(Department of Cardiology,Zhengzhou NO.7 People's Hospital,Zhengzhou 450000,China;不详)
出处 《中国循证心血管医学杂志》 2020年第3期364-369,共6页 Chinese Journal of Evidence-Based Cardiovascular Medicine
关键词 心肌梗死 慢血流 危险因素 Myocardial infarction Slow flow Risk factor
  • 相关文献

参考文献4

二级参考文献33

  • 1Collaborative Research Group of Reperfusion Therapy in Acute Myocardial Infarction.重组葡激酶与重组组织型纤溶酶原激活剂治疗急性心肌梗死的随机多中心临床试验[J].中华心血管病杂志,2007,35(8):691-696. 被引量:46
  • 2Durante A, Camici PG. Novel insights into an " old" phenomenon : the no reflow. Int J Cardiol,2015 ,187 :273-280.
  • 3Tranum-Jensen J, Janse MJ, Fiolet WT, et al. Tissue osmolality, cell swelling, and reperfusion in acute regional myocardial ischemia in the isolated porcine [ J]. Circ Res, 1981,49 (2) :364-381.
  • 4Yellon DM, Hausenloy DJ. Myocardial reperfusion injury [ J ]. N Engl J Med, 357 ( 2007 ) : 1121-1135.
  • 5Kaul S. The " noreflow" phenomenon following acute myocardial in- farction:Mechanisms and treatment options [ J ]. J Cardiol, 2014,64 (2) :77-85.
  • 6Niecoli G,Kharbanda RK, Crea F, et al. No-reflow: again prevention is better than treatment [ J ]. Eur Heart J,2010,31 (20) :2449-2455.
  • 7Galasso G, Sehiekofer S, D'Anna C, et al. No-Reflow phenomenon: pathophysiology, diagnosis, prevention, and treatment. A Review of the Current Literature and Future Perspectives [ J ]. Angiology, 2014,65 (3) :180-189.
  • 8Su Q, Li L, Liu Y. Short-term effect of verapamil on coronary no-reflow associated with pereutaneous coronary intervention in patients with a- cute coronary syndrome : a systematic review and meta-analysis of ran- domized controlled trials[ J ]. Clin Cardio1,2013,36 ( 8 ) :El 1 -El6.
  • 9Wendland Mr, Saee~l M-, Masui T, et al. Eehoplanar MR imaging of normal and isehemie myoeardium with gadodiamide injection[ J]. Ra- diology, 1993 ( 186 ) :535-542.
  • 10Aletras AH,Tilak GS,Natan~n A,et al. Retrospective determination of the area at risk for reperfused acute myocardial infarction with T2-weighted cardiac magnetic resonance imaging: histopathological and displacement encoding with stimulated echoes (DENSE) functional validations[ J ]. Cir- culation,2006,113(15) :1865-1870.

共引文献2404

同被引文献218

引证文献19

二级引证文献70

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部